● Recruiting

Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Condition: Advanced Non-Small Cell Lung Cancer · Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

PhasePhase 1

Planned participants144

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

This Phase Ib/III study evaluates the efficacy and safety of IBI351 in combination with chemotherapy in advanced non-squamous NSCLC with KRAS G12C mutation.

This description comes directly from the study's public registry record.

Talk to the study team

Haiyan Zhu · 0512-69566088 · haiyan.zhu@innoventbio.com

Always discuss trial participation with your own doctor first.

Locations (1)

Jilin Province Cancer Hospital

Jilin City, Changchun, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05504278